Primary intraosseous smooth muscle tumor of uncertain malignant potential: original report and molecular characterization

by Lauren Kropp, Gene P. Siegal, Garrett M. Frampton, Michael G. Rodriguez, Svetlana McKee, Robert M. Conry
Published 2016-11-01

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy

by Amélie Boichard, Timothy V. Pham, Huwate Yeerna, Aaron Goodman, Pablo Tamayo, Scott Lippman, Garrett M. Frampton, Igor F. Tsigelny, Razelle Kurzrock
Published 2019-03-01

The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors.

by Jacob Rinaldi, Ethan S Sokol, Ryan J Hartmaier, Sally E Trabucco, Garrett M Frampton, Michael E Goldberg, Lee A Albacker, Anneleen Daemen, Gerard Manning
Published 2020-01-01

Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report

by Hong Li, Weijie Ma, Ken Y. Yoneda, Elizabeth H. Moore, Yanhong Zhang, Lee L. Q. Pu, Garrett M. Frampton, Michael Molmen, Philip J. Stephens, Tianhong Li
Published 2017-02-01

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.

by James X Sun, Yuting He, Eric Sanford, Meagan Montesion, Garrett M Frampton, Stéphane Vignot, Jean-Charles Soria, Jeffrey S Ross, Vincent A Miller, Phil J Stephens, Doron Lipson, Roman Yelensky
Published 2018-02-01

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.

by Michael E Goldberg, Meagan Montesion, Lauren Young, James Suh, Joel Greenbowe, Mark Kennedy, Giuseppe Giaccone, Wallace L Akerley, Afshin Dowlati, Benjamin C Creelan, James K Hicks, Paul J Hesketh, Karen L Kelly, Jonathan W Riess, Vincent A Miller, Philip J Stephens, Garrett M Frampton, Siraj Ali, Jeffrey P Gregg, Lee A Albacker
Published 2018-01-01

Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors

by Cathy Zhou, Zilong Yuan, Weijie Ma, Lihong Qi, Angelique Mahavongtrakul, Ying Li, Hong Li, Jay Gong, Reggie R. Fan, Jin Li, Michael Molmen, Travis A. Clark, Dean Pavlick, Garrett M. Frampton, Brady Forcier, Elizabeth H. Moore, David K. Shelton, Matthew Cooke, Siraj M. Ali, Vincent A. Miller, Jeffrey P. Gregg, Philip J. Stephens, Tianhong Li
Published 2018-11-01

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

by Zachary R. Chalmers, Caitlin F. Connelly, David Fabrizio, Laurie Gay, Siraj M. Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, Steven Roels, Jared White, Geoffrey A. Otto, Jeffrey S. Ross, Levi Garraway, Vincent A. Miller, Phillip J. Stephens, Garrett M. Frampton
Published 2017-04-01

Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors

by Jonathan W. Riess, Shaila Rahman, Waleed Kian, Claire Edgerly, Andreas M. Heilmann, Russell Madison, Shakti H. Ramkissoon, Shai Shlomi Klaitman, Jon H. Chung, Sally E. Trabucco, Dexter X. Jin, Brian M. Alexander, Samuel J. Klempner, Lee A. Albacker, Garrett M. Frampton, Laila C. Roisman, Vincent A. Miller, Jeffrey S. Ross, Alexa B. Schrock, Jeffrey P. Gregg, Nir Peled, Ethan S. Sokol, Siraj M. Ali
Published 2021-10-01